Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Rating of "Moderate Buy" by Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $53.6667.

A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. HC Wainwright restated a "buy" rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a "strong-buy" rating in a report on Thursday, June 25th. Finally, Roth Capital reiterated a "buy" rating and set a $38.00 target price on shares of Capricor Therapeutics in a research report on Friday, May 15th.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $19.83 on Friday. The company's 50 day simple moving average is $25.47 and its 200-day simple moving average is $27.52. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -8.55 and a beta of 0.42. Capricor Therapeutics has a 1 year low of $4.30 and a 1 year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.04). Equities analysts expect that Capricor Therapeutics will post -0.49 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the transaction, the chief financial officer directly owned 8,223 shares of the company's stock, valued at $260,669.10. The trade was a 75.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 50,000 shares of company stock worth $1,551,658. Company insiders own 9.20% of the company's stock.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the stock. KBC Group NV purchased a new position in Capricor Therapeutics during the 1st quarter worth $44,000. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $43,000. Allworth Financial LP boosted its holdings in shares of Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 3,264 shares in the last quarter. State of Wyoming increased its stake in shares of Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company's stock worth $128,000 after acquiring an additional 1,913 shares during the period. Finally, Royal Bank of Canada increased its stake in shares of Capricor Therapeutics by 12.4% during the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company's stock worth $146,000 after acquiring an additional 557 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.